Ser1162

Site Information
CGsLDKtsPEMsNsN SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3201651
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:	breast cancer ( 7 ) , leukemia ( 10 ) , chronic myelogenous leukemia ( 10 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 4 , 5 ) , non-small cell lung adenocarcinoma ( 1 , 5 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 9 ) , Jurkat (T lymphocyte) ( 2 , 8 ) , K562 (erythroid) ( 6 , 10 ) , lung ( 1 ) , NCI-H2228 (pulmonary) ( 5 ) , NCI-H3122 (pulmonary) ( 4 ) , SKBr3 (breast cell) ( 7 )

References
1	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
4	Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
5	Rikova K (2013) CST Curation Set: 18458; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
8	Mulhern D (2011) CST Curation Set: 12572; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
9	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
10	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info